FDA Approved Products

190 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Active:Lifecycle: GrowthClear all
AKEEGA
niraparib tosylate monohydrate and abiraterone acetate
Growth
Johnson & Johnson
ORAL · TABLET
suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC)prostate cancer
2023
NDA
0/100
ALVAIZ
eltrombopag
Growth
Teva
ORAL · TABLET
thrombocytopenia in adultolder with persistent+8
2023
NDA
0/100
ALYFTREK
vanzacaftor, tezacaftor, and deutivacaftor
Growth
Vertex Pharmaceuticals
ORAL · TABLET
cystic fibrosis (CF) in patients aged 6 yearsolder+1
2024
NDA
0/100
APHEXDA
motixafortide
Growth
SUBCUTANEOUS · POWDER
combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collectionsubsequent autologous transplantation in patients with multiple myeloma+1
2023
PeptideNDA
0/100
AQNEURSA
levacetylleucine
Growth
IntraBio
ORAL · FOR SUSPENSION
neurological manifestations of Niemann-Pick disease type C (NPC) in adults
2024
NDA
0/100
ARBLI
losartan potassium
Growth
ORAL · SUSPENSION
hypertension in adultsolder+9
2025
NDA
0/100
ATTRUBY
acoramidis hydrochloride
Growth
BridgeBio Pharma
ORAL · TABLET
the cardiomyopathy of wild-typevariant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death+1
2024
NDA
0/100
AUGTYRO
repotrectinib
Growth
Bristol Myers Squibb
ORAL · CAPSULE
• are locally advancedmetastatic+3
2023
SMNDA
0/100
AURLUMYN
iloprost
Growth
INTRAVENOUS · SOLUTION
severe frostbite in adults to reduce the risk of digit amputations
2024
NDA
0/100
BEIZRAY
docetaxel
Growth
INTRAVENOUS · SOLUTION
metastatic breast cancer after failure of prior chemotherapymetastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy+6
2024
NDA
0/100
BOSULIF
bosutinib
Growth
Pfizer
ORAL · CAPSULE
• adultolder with chronic phase Ph+ chronic myelogenous leukemia (CML)+4
2023
SMNDA
0/100
BRIXADI
buprenorphine
Growth
Braeburn Pharmaceuticals
SUBCUTANEOUS · SOLUTION, EXTENDED RELEASE
moderate to severe opioid use disorder in patients
2023
NDA
0/100
BRYNOVIN
sitagliptin hydrochloride oral
Growth
R-Pharm US
ORAL · SOLUTION
type 2 diabetes mellitus
2025
NDA
0/100
BYNFEZIA PEN
octreotide acetate
Growth
Fosun Pharma
SUBCUTANEOUS · SOLUTION
blood levels of growth hormone (GH)insulin gro wth factor-1 (I GF-1+3
2024
PeptideNDA
0/100
BYQLOVI
clobetasol propionate
Growth
OPHTHALMIC · SUSPENSION/DROPS
post-operative inflammationpain following ocular surgery
2024
NDA
0/100
CABTREO
clindamycin phosphate/benzoyl peroxide/adapalene
Growth
Bausch + Lomb
TOPICAL · GEL
2023
NDA
0/100
COBENFY
xanomeline and trospium chloride
Growth
Bristol Myers Squibb
ORAL · CAPSULE
schizophrenia in adultsschizophrenia
2024
NDA
0/100
COMBOGESIC IV
acetaminophen and ibuprofen injection
Growth
Hikma
INTRAVENOUS · SOLUTION
moderate to severe painless
2023
NDA
0/100
CRENESSITY
crinecerfont
Growth
ORAL · SOLUTION
2024
NDA
0/100
CRENESSITY
crinecerfont
Growth
ORAL · CAPSULE
2024
NDA
0/100
CREXONT
carbidopa and levodopa
Growth
ORAL · CAPSULE, EXTENDED RELEASE
Parkinson's diseasepost-encephalitic parkinsonism+2
2024
NDA
0/100
DANZITEN
nilotinib
Growth
R-Pharm US
ORAL · TABLET
accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistantintolerant to prior therapy+1
2024
SMNDA
0/100
DEFENCATH
taurolidine and heparin
Growth
CorMedix
N/A · SOLUTION
catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC)incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC)
2023
NDA
0/100
DUVYZAT
givinostat
Growth
Italfarmaco Research
ORAL · SUSPENSION
Duchenne muscular dystrophy (DMD) in patients 6 years of ageolder
2024
SMNDA
0/100